Phospho-MAP2K7 (T275) Antibody

說明書

中文名稱：

磷酸化-MAP2K7 (T275)兔多克隆抗體
貨號：

CSB-PA030308
規格：

￥1090
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O14733
基因名：

MAP2K7
別名：

c-Jun N-terminal kinase kinase 2 antibody; Dual specificity mitogen activated protein kinase kinase 7 antibody; Dual specificity mitogen-activated protein kinase kinase 7 antibody; JNK activating kinase 2 antibody; JNK kinase 2 antibody; JNK-activating kinase 2 antibody; JNKK 2 antibody; Jnkk-2 antibody; Jnkk2 antibody; MAP kinase kinase 7 antibody; MAP2K7 antibody; MAPK/ERK kinase 7 antibody; MAPKK 7 antibody; MAPKK-7 antibody; MAPKK7 antibody; MEK 7 antibody; Mitogen Activated Protein Kinase kinase 7 antibody; MKK 7 antibody; MKK-7 antibody; MKK7 antibody; MP2K7_HUMAN antibody; PRKMK 7 antibody; PRKMK-7 antibody; PRKMK7 antibody; SAPK kinase 4 antibody; SAPKK-4 antibody; SAPKK4 antibody; Sek 2 antibody; Sek-2 antibody; Sek2 antibody; SKK4 antibody; stress-activated protein kinase kinase 4 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Synthesized peptide derived from Human MEK-7 around the phosphorylation site of T275.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, IHC, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:100-1:300
ELISA	1:20000

Protocols：

Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by proinflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE.
基因功能參考文獻：
1. The assessment of the interaction between GADD45beta and MKK7 and the elucidation of the recognition surfaces between DTP3 and MKK7 significantly advance the understanding of the mechanism underlying the inhibition of the GADD45beta/MKK7 interaction by DTP3 and pave the way to the design of small-molecule DTP3 analogues. PMID: 29572137
2. In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study PMID: 28444112
3. the p.Glu116Lys rare variant in MAP2K7 predisposes its carriers to develop COPD, which would provide a useful genetic biomarker for COPD susceptibility in Chinese. PMID: 28120412
4. Combination BRAF and MEK inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events. PMID: 28561662
5. The latter insight is likely to promote the production of allosteric MAP2K7 inhibitors. PMID: 28890347
6. MEK activation cooperates with Cdkn2a and Pten inactivation to induce melanoma PMID: 28263969
7. MKK7 undergoes neddylation in human breast cancer cells PMID: 26364603
8. In an Eastern Chinese population, carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC. PMID: 27861856
9. combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers PMID: 26351322
10. our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF/MAPK pathway PMID: 26649302
11. Crystal structures of the wild type and C218S mutant of MAP2K7 were determined. Cys218 plays a crucial role in configuring an auto-inhibition form of MAP2K7. PMID: 26987717
12. We found that the MKK7 p.Glu116Lys rare polymorphism was significantly associated with lung cancer risk, progression and prognosis PMID: 27028764
13. we explored the effects of selumetinib in combination with gefitinib in a panel of TNBC cells, in order to evaluate whether the simultaneous blockade of the EGFR and the RAS/MEK/ERK pathway might increase the antitumor activity of selumetinib in TNBC. PMID: 25959272
14. a widespread role for the JNK-CELF2 axis in controlling splicing during T-cell activation, including a specific role in propagating JNK signaling. PMID: 26443849
15. This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways PMID: 25899612
16. BCR-ABL promotes PTEN downregulation through a MEK dependent pathway. PMID: 25343485
17. In conclusion, the expression of hepatitis B virus core protein sensitized hepatocytes to TNF-alpha-induced apoptosis by disrupting the interaction between MKK7 and RACK1. PMID: 25428880
18. Combination of AAG8 antagonist and very low concentration of a MEK inhibitor synergistically restricts the growth of drug-resistant cells. PMID: 24634165
19. MKK7 is a major functional target of miR-493, and its suppression thwarts liver metastasis of colon cancer cells. PMID: 24533778
20. Gadd45B protects the liver through two entirely different processes: binding MKK7 to block damaging signal transduction or binding CAR to coactivate anabolic transcription. (Review) PMID: 24104474
21. the results imply that reduced function of the MAP2K7-c-Jun N-terminal kinase (JNK) signalling cascade may underlie some of the neurochemical changes and core symptoms in schizophrenia. PMID: 22899651
22. Overexpressed RACK1 augments JNK activity and thereby promotes hepatocellular carcinoma growth through directly binding to MKK7 and enhancing MKK7 activity. PMID: 22903704
23. Taxol induces apoptosis in chronic myelogenous leukemia cells by inducing intracellular oxidative stress and JNK activation pathway. PMID: 21074392
24. Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. PMID: 22159816
25. a novel function for the stress kinase MKK7 as a regulator of the circadian clock in mammalian cells at steady state. PMID: 22267733
26. WDR62 associates directly with the MKK7beta1 isoform independently of JNK binding, but fails to interact with MKK7alpha1. PMID: 21749326
27. ML-1 activated a MAP kinase and an extracellular signal-regulated kinase (ERK)1/2 but not p38 or the c-Jun N-terminal kinase (JNK) PMID: 11891214
28. JNK, MKK-4, and MKK-7 form an active signaling complex in rheumatoid arthritis and this novel JNK signalsome is activated in response to IL-1 and migrates to the nucleus. PMID: 13130464
29. report the cloning of hMKK7gamma1, the human homolog of murine MKK7gamma1 PMID: 16442502
30. MKK7 contains three JNK-docking sites that interact to selectively bind JNK and contribute to JNK signal transmission and specificity PMID: 16533805
31. data indicate that only MKK-7 is required for JNK activation in fibroblast-like synoviocytes after cytokine stimulation PMID: 16802349
32. Association of Gadd45beta with MKK7 involves a network of interactions mediated by its putative helices alpha3 and alpha4 and loops 1 and 2 PMID: 17485467
33. p38 MAPK inhibitors SB202190 and SB203580 activated JNK via MLK-3/MKK7 pathway. PMID: 18222647
34. The results suggest the occurrence of a large complex containing at least an MKK7-Gadd45 beta:Gadd45 beta-MKK7 tetrameric unit whose complexity could be further increased by the dimeric nature of the isolated MKK7. PMID: 18343408
35. Disruption of signaling through MKK7 yields differential response in hypoxic colon cancer cells treated with oxaliplatin. PMID: 18436711
顯示更多

收起更多
亞細胞定位：

Nucleus. Cytoplasm.
蛋白家族：

Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily
組織特異性：

Ubiquitous; with highest level of expression in skeletal muscle. Isoform 3 is found at low levels in placenta, fetal liver, and skeletal muscle.
數據庫鏈接：

HGNC: 6847

OMIM: 603014

KEGG: hsa:5609

STRING: 9606.ENSP00000381066

UniGene: Hs.531754

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human